AMBP and chronic kidney disease: This is in accordance with current evidence on the promising role of other biomarkers related to inflammation in the progression of CKD, including those of tubule cell injury, e.g., KIM-1 and MCP-1, and those of mark tubule cell dysfunction (e.g., α1M and UMOD) [32], as well as mGPS [19].